2 November 2015 - IQWiG finds an indication of a considerable additional benefit in comparison with vitamin K antagonists for the prevention of stroke and systemic embolism: stroke, bleeding and severe side effects occurred less frequently with the use of edoxaban tosylate.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/edoxaban-considerable-added-benefit-for-certain-patients.7001.html [English]